What It Is
Ibogaine Microdosing: Definition and Context
Ibogaine microdosing refers to the practice of taking sub-perceptual doses of ibogaine — typically 1 to 5 mg/kg body weight — on a repeated schedule. At these doses, ibogaine does not produce the visionary experience, significant nausea, ataxia, or other acute effects associated with a flood dose (10-20 mg/kg). The goal of microdosing is to engage ibogaine's neuroplasticity and neurochemical modulation pathways at a level that supports ongoing recovery without the intensity of a full treatment session.
The concept parallels psilocybin microdosing, which has gained significant attention for mood and cognitive enhancement. However, ibogaine microdosing carries a critical distinction: even at low doses, ibogaine affects cardiac function through hERG potassium channel blockade. This means ibogaine microdosing requires more medical consideration than psilocybin microdosing and should not be self-administered without cardiac screening.
MindScape's position is straightforward: the strongest evidence supports flood-dose ibogaine as the primary therapeutic intervention. Microdosing may offer supplementary value as part of an aftercare protocol, but it is not a substitute for the comprehensive neurochemical reset that a full ibogaine treatment provides.
Flood Dose vs. Microdose
A flood dose (10-20 mg/kg) produces a complete neurochemical reset — opioid receptor sensitivity restoration, deep psychological insight, and large-scale neuroplasticity via GDNF upregulation. A microdose (1-5 mg/kg) does not produce these effects at clinically significant levels. The two are fundamentally different interventions with different therapeutic profiles.
- Flood dose: 12-24 hour experience, requires medical supervision, comprehensive reset
- Microdose: no perceptible psychoactive effects, may support maintenance neuroplasticity
- Flood dose has strong published evidence (Noller 2018, Davis 2017); microdosing does not
- Both carry cardiac considerations — flood dose more so, but microdosing is not zero-risk
Theoretical Mechanisms
How Ibogaine Microdosing May Work
GDNF Maintenance
The strongest theoretical rationale. Flood-dose ibogaine upregulates Glial Cell Line-Derived Neurotrophic Factor, promoting neuronal survival and repair. Low-dose exposure may maintain elevated GDNF levels beyond the natural decline period, extending the neuroplasticity window that supports lasting recovery. This has not been confirmed in human microdosing studies.
Noribogaine Extension
Ibogaine is metabolized to noribogaine, which has a long half-life and provides sustained serotonin transporter inhibition. Periodic microdoses may replenish noribogaine levels, extending the mood-stabilizing and anti-craving effects that patients experience in the months following a flood dose. Pharmacokinetic modeling supports this, but clinical trials are needed.
Opioid Receptor Modulation
Low-dose ibogaine may maintain the opioid receptor sensitivity reset achieved during the flood dose. For patients in addiction recovery, this could reduce the risk of relapse by keeping receptor systems in a recalibrated state. The mechanism is plausible based on ibogaine's known receptor pharmacology, but unproven at microdose levels.
Kappa-Opioid Regulation
Ibogaine's modulation of kappa-opioid receptors affects mood, stress response, and pain perception. Low-dose maintenance may provide ongoing anti-dysphoric effects — potentially valuable for patients with comorbid depression or chronic pain. This is the most speculative of the proposed mechanisms.
What the Science Says
Evidence Assessment: Honest and Current
As of March 2026, no randomized controlled trials (RCTs) of ibogaine microdosing protocols have been published. The evidence base consists of: (1) established pharmacology of ibogaine at therapeutic doses, (2) animal studies demonstrating GDNF upregulation, (3) anecdotal reports from patients and practitioners, and (4) pharmacokinetic modeling suggesting low doses may engage target receptors. This is a reasonable foundation for hypothesis generation but not sufficient for definitive clinical claims.
The strongest ibogaine evidence supports the flood dose. Noller et al. (2018) published the first prospective observational study of ibogaine for opioid dependence, documenting significant reductions in opioid withdrawal symptoms and sustained abstinence. Davis et al. (2017) reported on ibogaine's effects on opioid-dependent individuals in an observational study. Neither study investigated microdosing protocols.
MindScape is committed to evidence-informed practice. We recommend the flood dose as the primary intervention because the evidence supports it. We offer microdosing guidance as part of aftercare because the pharmacological rationale is sound, the risk profile at low doses is manageable with screening, and patient demand exists. We are transparent that microdosing-specific evidence is emerging, not established.
Protocol Comparison
Ibogaine Microdosing vs. Psilocybin Microdosing
| Ibogaine | Psilocybin Microdosing | |
|---|---|---|
| Primary Receptors | Serotonin, dopamine, kappa-opioid, NMDA, nicotinic | Serotonin 5-HT2A primarily |
| Cardiac Risk | hERG blockade present even at low doses — cardiac screening recommended | No significant cardiac risk at microdose levels |
| Addiction Recovery | May maintain opioid receptor reset and reduce relapse risk | Not specifically anti-addictive — mood support primarily |
| GDNF Upregulation | Documented at therapeutic doses; theoretical at microdose | Not a known mechanism of psilocybin |
| Research Base | No published RCTs for microdosing specifically | Several published studies, mixed results on efficacy |
| Legal Status | Unscheduled in Mexico; Schedule I in the US | Schedule I in the US; decriminalized in some jurisdictions |
For detailed information about the full ibogaine flood dose — the primary treatment that MindScape recommends — see how ibogaine works, our safety guide, and our complete side effects page. The cardiac considerations for microdosing are covered in our cardiac screening protocol.
Our aftercare program is where microdosing guidance is incorporated — as one component of a comprehensive 90-day integration support system. For patients exploring alternatives, our ibogaine vs ketamine and 5-MeO-DMT vs ibogaine comparisons provide context on other psychedelic-assisted approaches.
MindScape's Approach
How We Incorporate Microdosing in Aftercare
Full Flood Dose First
The foundational treatment is always the medically supervised flood-dose ibogaine session. This produces the comprehensive neurochemical reset that microdosing cannot replicate. Microdosing is only considered after the primary treatment is complete.
Cardiac Baseline Established
During the primary treatment, we establish your cardiac baseline via 12-lead EKG. This data informs whether aftercare microdosing is appropriate for you specifically. Patients with any cardiac concerns are counseled against home microdosing.
Individualized Protocol Design
For patients who are appropriate candidates, our medical team designs an individualized microdosing protocol — dose, frequency, duration, and monitoring recommendations. This is not a one-size-fits-all recommendation.
Integration + Monitoring
Microdosing guidance is delivered within the context of our 90-day integration program. Patients report on their experience, any side effects, and subjective efficacy. The protocol is adjusted based on ongoing feedback and clinical judgment.
Honest Assessment of Outcomes
We track and discuss microdosing outcomes openly with patients. If the protocol does not appear to be providing benefit, we recommend discontinuation rather than continuation for its own sake. Evidence-informed practice means being willing to stop what does not work.
Safety Considerations
What Anyone Considering Ibogaine Microdosing Should Know
Cardiac Screening Is Not Optional
Ibogaine blocks hERG potassium channels at any dose. While the degree of QTc prolongation is lower at microdose levels, individuals with pre-existing cardiac conditions, prolonged QTc intervals, or concurrent use of QTc-prolonging medications face real risk. Baseline EKG screening should precede any ibogaine microdosing protocol.
Drug Interactions Persist
The medication contraindications that apply to flood-dose ibogaine — SSRIs, MAOIs, methadone, stimulants — also apply to microdosing. The interaction risk is dose-dependent but not eliminated at low doses. Full medication review is essential before starting any ibogaine microdosing regimen.
Source Quality Matters
Ibogaine obtained from unverified sources may have inconsistent potency, contamination, or incorrect identification. Microdosing with material of unknown purity introduces additional risk. Pharmaceutical-grade ibogaine HCl from a verified supplier is the only appropriate source for any ibogaine protocol.
Self-Administration Risk
Ibogaine microdosing without medical guidance means no cardiac screening, no drug interaction review, and no professional monitoring. The growing popularity of self-administered ibogaine microdosing in the psychedelic community is concerning precisely because it bypasses the safety measures that make ibogaine therapy safe.
Common Questions
Ibogaine Microdosing — Frequently Asked Questions
Explore Ibogaine Treatment Resources
Start a Confidential Conversation
100% Confidential · No Obligation · Response Within 24 Hours
100% Confidential · No Obligation · Available 7 Days a Week